Literature DB >> 19779392

Safety experience with caspofungin in pediatric patients.

Theoklis Zaoutis1, Thomas Lehrnbecher, Andreas H Groll, William J Steinbach, Hasan S Jafri, Johan Maertens, Angela L Ngai, Joseph W Chow, Arlene F Taylor, Kim M Strohmaier, Michael Bourque, Susan K Bradshaw, Maria Petrecz, Nicholas A Kartsonis.   

Abstract

We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19779392     DOI： 10.1097/INF.0b013e3181af5a15

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  8 in total

1.  A case of pediatric acute lymphoblastic leukemia with invasive candidiasis: short review.

Authors:  S P Verma; B Dubashi; P Narayanan; D Basu; T K Dutta; K M Dhanraj
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-12       Impact factor: 0.900

2.  Off-label use of antimicrobials in neonates in a tertiary children's hospital.

Authors:  Niina Laine; Ann Marie Kaukonen; Kalle Hoppu; Marja Airaksinen; Harri Saxen
Journal:  Eur J Clin Pharmacol       Date:  2017-01-18       Impact factor: 2.953

3.  Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.

Authors:  Brian T Fisher; Theoklis Zaoutis; Christopher C Dvorak; Michael Nieder; Danielle Zerr; John R Wingard; Colleen Callahan; Doojduen Villaluna; Lu Chen; Ha Dang; Adam J Esbenshade; Sarah Alexander; Joseph M Wiley; Lillian Sung
Journal:  JAMA       Date:  2019-11-05       Impact factor: 56.272

4.  A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.

Authors:  Christopher C Dvorak; Brian T Fisher; Adam J Esbenshade; Michael L Nieder; Sarah Alexander; William J Steinbach; Ha Dang; Doojduen Villaluna; Lu Chen; Micah Skeens; Theoklis E Zaoutis; Lillian Sung
Journal:  J Pediatric Infect Dis Soc       Date:  2021-04-30       Impact factor: 3.164

Review 5.  Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.

Authors:  Athanasios Tragiannidis; Charalampos Dokos; Thomas Lehrnbecher; Andreas H Groll
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

Review 6.  Invasive Aspergillosis in Children: Update on Current Guidelines.

Authors:  Athanasia Apsemidou; Nikolaos Petridis; Timoleon-Achilleas Vyzantiadis; Athanasios Tragiannidis
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

7.  Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.

Authors:  Nathan P Wiederhold; Lydia A Herrera
Journal:  Clin Med Insights Pediatr       Date:  2012-06-07

Review 8.  Pediatric Invasive Aspergillosis.

Authors:  Rachel L Wattier; Lynn Ramirez-Avila
Journal:  J Fungi (Basel)       Date:  2016-06-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.